These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11408505)

  • 41. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
    Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
    Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
    Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
    J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evolution of unbalanced gain of distal chromosome 2p in neuroblastoma.
    Stallings RL; Carty P; McArdle L; Mullarkey M; McDermott M; O'Meara A; Ryan E; Catchpoole D; Breatnach F
    Cytogenet Genome Res; 2004; 106(1):49-54. PubMed ID: 15218241
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group.
    George RE; Variend S; Cullinane C; Cotterill SJ; McGuckin AG; Ellershaw C; Lunec J; Pearson AD;
    Med Pediatr Oncol; 2001 Jan; 36(1):169-76. PubMed ID: 11464876
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MYCN protein expression as a predictor of neuroblastoma prognosis.
    Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
    Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
    Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
    Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Detection of Genetic Parameters for Prognostic Stratification of Neuroblastoma Using Multiplex Ligation-Dependent Probe Amplification Technique.
    Tumer S; Altungoz O; Bagci O; Olgun HN
    Genet Test Mol Biomarkers; 2016 Feb; 20(2):74-80. PubMed ID: 26790040
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
    Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
    J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma.
    Christiansen H; Sahin K; Berthold F; Hero B; Terpe HJ; Lampert F
    Eur J Cancer; 1995; 31A(4):541-4. PubMed ID: 7576963
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
    Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
    Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The neuroblastoma, "enfant terrible" among pediatric tumors].
    Laureys G
    Verh K Acad Geneeskd Belg; 2003; 65(1):5-23; discussion 23-8. PubMed ID: 12802894
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chromosome 17/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma.
    Theissen J; Oberthuer A; Hombach A; Volland R; Hertwig F; Fischer M; Spitz R; Zapatka M; Brors B; Ortmann M; Simon T; Hero B; Berthold F
    Genes Chromosomes Cancer; 2014 Aug; 53(8):639-49. PubMed ID: 24737690
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction.
    Morowitz M; Shusterman S; Mosse Y; Hii G; Winter CL; Khazi D; Wang Q; King R; Maris JM
    Mod Pathol; 2003 Dec; 16(12):1248-56. PubMed ID: 14681326
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Biological markers for the prognosis of neuroblastoma: proposal of a method of analysis].
    Combaret V; Delattre O; Bénard J; Favrot MC
    Bull Cancer; 1998 Mar; 85(3):262-6. PubMed ID: 9752317
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA.
    Combaret V; Bréjon S; Iacono I; Schleiermacher G; Pierron G; Ribeiro A; Bergeron C; Marabelle A; Puisieux A
    Pediatr Blood Cancer; 2011 May; 56(5):757-61. PubMed ID: 21370407
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic alterations involving chromosome 1p in children with neuroblastoma.
    Avigad S; Tamir Y; Yaniv I; Goshen J; Kaplinsky C; Cohen IJ; Zaizov R
    Isr J Med Sci; 1994 Aug; 30(8):639-41. PubMed ID: 7913920
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Morphologic and molecular cytogenetics in neuroblastoma.
    Avet-Loiseau H; Venuat AM; Benard J; Leibovitch MP; Hartmann O; Bernheim A
    Cancer; 1995 Apr; 75(7):1694-9. PubMed ID: 8826929
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chromosome 1p and 11q deletions and outcome in neuroblastoma.
    Attiyeh EF; London WB; Mossé YP; Wang Q; Winter C; Khazi D; McGrady PW; Seeger RC; Look AT; Shimada H; Brodeur GM; Cohn SL; Matthay KK; Maris JM;
    N Engl J Med; 2005 Nov; 353(21):2243-53. PubMed ID: 16306521
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease.
    Mora J; Cheung NK; Chen L; Qin J; Gerald W
    Cancer; 2001 Jan; 91(2):435-42. PubMed ID: 11180092
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma.
    Vandesompele J; Baudis M; De Preter K; Van Roy N; Ambros P; Bown N; Brinkschmidt C; Christiansen H; Combaret V; Lastowska M; Nicholson J; O'Meara A; Plantaz D; Stallings R; Brichard B; Van den Broecke C; De Bie S; De Paepe A; Laureys G; Speleman F
    J Clin Oncol; 2005 Apr; 23(10):2280-99. PubMed ID: 15800319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.